Scott A. Monk

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 205 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Transient Expression of CYP1A1 in Rat Epithelial Cells Cultured in Suspension

Scott A. Monk, Michael S. Denison, Robert H. Rice · Archives of Biochemistry and Biophysics · 2001 · 32 citations

Life Sciences, Biochemistry, Molecular Biology +6

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor

David L. McKinzie, Leonard L. Winneroski, Steven J. Green et al. · Journal of Medicinal Chemistry · 2021 · 28 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).

John R. Sims, Katherine J. Selzler, AnnCatherine M. Downing et al. · PubMed · 2017 · 22 citations

Medicine, Neurology, Pharmacology +17